{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:48:55Z","timestamp":1767134935949,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd006945.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,3,8]],"date-time":"2017-03-08T00:00:00Z","timestamp":1488931200000}}],"reference-count":52,"publisher":"Wiley","issue":"3","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006945.pub4","type":"journal-article","created":{"date-parts":[[2017,3,8]],"date-time":"2017-03-08T11:47:04Z","timestamp":1488973624000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer"],"prefix":"10.1002","volume":"2017","author":[{"given":"Daniel KL","family":"Cheuk","sequence":"first","affiliation":[{"name":"The University of Hong Kong, Queen Mary Hospital; Department of Pediatrics and Adolescent Medicine; Pokfulam Road Hong Kong China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan KS","family":"Chiang","sequence":"additional","affiliation":[{"name":"The University of Hong Kong, Queen Mary Hospital; Department of Pediatrics and Adolescent Medicine; Pokfulam Road Hong Kong China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Godfrey CF","family":"Chan","sequence":"additional","affiliation":[{"name":"The University of Hong Kong, Queen Mary Hospital; Department of Pediatrics and Adolescent Medicine; Pokfulam Road Hong Kong China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shau Yin","family":"Ha","sequence":"additional","affiliation":[{"name":"The University of Hong Kong, Queen Mary Hospital; Department of Pediatrics and Adolescent Medicine; Pokfulam Road Hong Kong China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,3,8]]},"reference":[{"issue":"10","key":"10.1002\/14651858.CD006945.pub4-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1182\/blood.V97.10.2998","article-title":"A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis","volume":"97","author":"Goldman","year":"2001","journal-title":"Blood"},{"issue":"4","key":"10.1002\/14651858.CD006945.pub4-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s12185-009-0402-6","article-title":"A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome","volume":"90","author":"Kikuchi","year":"2009","journal-title":"International Journal of Hematology"},{"issue":"5","key":"10.1002\/14651858.CD006945.pub4-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1093\/annonc\/mdf134","article-title":"Urate-oxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia, treated in the Soci\u00e9t\u00e9 Fran\u00e7aise d'Oncologie P\u00e9diatrique LMB89 protocol","volume":"13","author":"Patte","year":"2002","journal-title":"Annals of Oncology"},{"issue":"11","key":"10.1002\/14651858.CD006945.pub4-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1038\/sj.leu.2400850","article-title":"Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies","volume":"11","author":"Pui","year":"1997","journal-title":"Leukemia"},{"issue":"1","key":"10.1002\/14651858.CD006945.pub4-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF02893442","article-title":"Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin's lymphoma","volume":"13","author":"R\u00e9nyi","year":"2007","journal-title":"Pathology Oncology Research"},{"issue":"2","key":"10.1002\/14651858.CD006945.pub4-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.anpedi.2009.10.011","article-title":"Rasburicase versus allopurinol in the treatment of hyperuricaemia in tumour lysis syndrome","volume":"72","author":"S\u00e1nchez Tatay","year":"2010","journal-title":"Anales de Pediatr\u00eda"},{"issue":"3","key":"10.1002\/14651858.CD006945.pub4-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s00277-003-0608-2","article-title":"Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma\/leukemia before and after introduction of prophylactic use of urate oxidase","volume":"82","author":"W\u00f6ssmann","year":"2003","journal-title":"Annals of Hematology"},{"issue":"27","key":"10.1002\/14651858.CD006945.pub4-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.1200\/JCO.2009.26.8896","article-title":"Control of plasma uric acid in adults at risk for tumor lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone-results of a multicenter phase III study","volume":"28","author":"Cortes","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD006945.pub4-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1349-7006.2008.01047.x","article-title":"Safety and efficacy of rasburicase (SR29142) in a Japanese phase II study","volume":"100","author":"Ishizawa","year":"2009","journal-title":"Cancer Science"},{"issue":"6","key":"10.1002\/14651858.CD006945.pub4-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1093\/annonc\/mdr490","article-title":"A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome","volume":"23","author":"Vadhan-Raj","year":"2012","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD006945.pub4-BIB0011|cit11","unstructured":"NCT00199043 Randomised phase III trial of effectivity and safety of rasburicase compared with allopurinol for treatment of hyperuricemia in patients with acute lymphoblastic leukemia or high-grade NHL with high risk of tumor lysis syndrome (> 15 yrs) clinicaltrials.gov\/ct2\/show\/NCT00199043?term=NCT00199043&rank=1"},{"key":"10.1002\/14651858.CD006945.pub4-BIB0012|cit12","unstructured":"NCT01200485 A randomized phase 2 study to evaluate the efficacy of rasburicase in patients at risk for TLS during two cycles of chemotherapy clinicaltrials.gov\/ct2\/show\/NCT01200485?term=NCT01200485&rank=1"},{"issue":"1","key":"10.1002\/14651858.CD006945.pub4-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/1042819021000054661","article-title":"Incidence, medical resource utilisation and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin's lymphoma in four European countries","volume":"44","author":"Annemans","year":"2003","journal-title":"Leukemia & Lymphoma"},{"issue":"4","key":"10.1002\/14651858.CD006945.pub4-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00520-002-0435-3","article-title":"Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients","volume":"11","author":"Annemans","year":"2003","journal-title":"Supportive Care in Cancer"},{"issue":"3","key":"10.1002\/14651858.CD006945.pub4-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1365-2710.2011.01260.x","article-title":"A review of tumour lysis syndrome with targeted therapies and the role of rasburicase","volume":"36","author":"Bose","year":"2011","journal-title":"Journal of Clinical Pharmacy and Therapeutics"},{"issue":"5","key":"10.1002\/14651858.CD006945.pub4-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/cncr.11612","article-title":"Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study","volume":"98","author":"Bosly","year":"2003","journal-title":"Cancer"},{"issue":"1","key":"10.1002\/14651858.CD006945.pub4-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2004.05094.x","article-title":"Tumour lysis syndrome: new therapeutic strategies and classification","volume":"127","author":"Cairo","year":"2004","journal-title":"British Journal of Haematology"},{"issue":"4","key":"10.1002\/14651858.CD006945.pub4-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.1365-2141.2010.08143.x","article-title":"Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus","volume":"149","author":"Cairo","year":"2010","journal-title":"British Journal of Haematology"},{"issue":"23","key":"10.1002\/14651858.CD006945.pub4-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"4402","DOI":"10.1200\/JCO.2003.04.115","article-title":"Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study","volume":"21","author":"Coiffier","year":"2003","journal-title":"Journal of Clinical Oncology"},{"issue":"16","key":"10.1002\/14651858.CD006945.pub4-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1200\/JCO.2007.15.0177","article-title":"Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review","volume":"26","author":"Coiffier","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006945.pub4-BIB0021|cit21","unstructured":"Deeks JJ Higgins JPT Altman DG (editors) Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.handbook.cochrane.org"},{"key":"10.1002\/14651858.CD006945.pub4-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006945.pub4-BIB0023|cit23","unstructured":"McMaster University, Evidence Prime, Inc. GRADEpro Guideline Development Tool 2015"},{"issue":"8","key":"10.1002\/14651858.CD006945.pub4-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJM196902202800806","article-title":"Urinary xanthine stones - a rare complication of allopurinol therapy","volume":"280","author":"Greene","year":"1969","journal-title":"The New England Journal of Medicine"},{"issue":"7517","key":"10.1002\/14651858.CD006945.pub4-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1136\/bmj.331.7517.623","article-title":"Fatal allopurinol hypersensitivity syndrome after treatment of asymptomatic hyperuricemia","volume":"331","author":"Gutierrez-Macias","year":"2005","journal-title":"BMJ"},{"issue":"11","key":"10.1002\/14651858.CD006945.pub4-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD006945.pub4-BIB0027|cit27","unstructured":"Higgins JPT Altman DG Sterne JAC (editors) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"12","key":"10.1002\/14651858.CD006945.pub4-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1038\/sj.leu.2403161","article-title":"Successful treatment of hyperuricemia with low doses of recombinant urate oxidase in four patients with hematologic malignancy and tumor lysis syndrome","volume":"17","author":"Hummel","year":"2003","journal-title":"Leukemia"},{"issue":"2","key":"10.1002\/14651858.CD006945.pub4-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1592\/phco.26.2.242","article-title":"Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy","volume":"26","author":"Hutcherson","year":"2006","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1002\/14651858.CD006945.pub4-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/sj.leu.2403566","article-title":"Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial","volume":"19","author":"Jeha","year":"2005","journal-title":"Leukemia"},{"key":"10.1002\/14651858.CD006945.pub4-BIB0031|cit31","unstructured":"Kremer LCM Jellema P Leclercq E Noorman JK Van Dalen EC Cochrane Childhood Cancer Group About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2016 Issue 7. Art. No.: CHILDCA"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006945.pub4-BIB0032|cit32","first-page":"237b","article-title":"High efficacy of recombinant urate oxidase in prevention of renal failure related to tumor lysis syndrome","volume":"92","author":"Lascombes","year":"1998","journal-title":"Blood"},{"issue":"11","key":"10.1002\/14651858.CD006945.pub4-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1345\/aph.1D111","article-title":"Treatment of impending tumor lysis with single-dose rasburicase","volume":"37","author":"Lee","year":"2003","journal-title":"The Annals of Pharmacotherapy"},{"issue":"4","key":"10.1002\/14651858.CD006945.pub4-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.leukres.2004.09.004","article-title":"A single dose of rasburicase is sufficient for the treatment of hyperuricemia in patients receiving chemotherapy","volume":"29","author":"Liu","year":"2005","journal-title":"Leukemia Research"},{"issue":"6","key":"10.1002\/14651858.CD006945.pub4-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1592\/phco.26.6.806","article-title":"Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults","volume":"26","author":"McDonnell","year":"2006","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.1002\/14651858.CD006945.pub4-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/sj.leu.2402847","article-title":"Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002","volume":"17","author":"Navolanic","year":"2003","journal-title":"Leukemia"},{"issue":"3","key":"10.1002\/14651858.CD006945.pub4-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1200\/JCO.2001.19.3.697","article-title":"Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma","volume":"19","author":"Pui","year":"2001","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"10.1002\/14651858.CD006945.pub4-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1038\/sj.leu.2402235","article-title":"Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial","volume":"15","author":"Pui","year":"2001","journal-title":"Leukemia"},{"issue":"8","key":"10.1002\/14651858.CD006945.pub4-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/ncponc0581","article-title":"The management of tumor lysis syndrome","volume":"3","author":"Rampello","year":"2006","journal-title":"Nature Clinical Practice Oncology"},{"key":"10.1002\/14651858.CD006945.pub4-BIB0040|cit40","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014"},{"key":"10.1002\/14651858.CD006945.pub4-BIB0041|cit41","unstructured":"Sanofi-Synthelabo Elitek (rasburicase) product monograph products.sanofi-aventis.us\/elitek\/elitek.html"},{"key":"10.1002\/14651858.CD006945.pub4-BIB0042|cit42","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JPT Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD006945.pub4-BIB0043|cit43","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JPT Deeks JJ Glasziou P et al (editors) Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"4","key":"10.1002\/14651858.CD006945.pub4-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/pbc.20555","article-title":"Recombinant urate oxidase (rasburicase) for the treatment of hyperuricemia in pediatric patients with hematologic malignancies: results of a compassionate prospective multicenter study in Korea","volume":"46","author":"Shin","year":"2006","journal-title":"Pediatric Blood and Cancer"},{"key":"10.1002\/14651858.CD006945.pub4-BIB0045|cit45","unstructured":"IBM Corporation IBM SPSS Statistics for Windows, Version 19.0 2010"},{"issue":"12","key":"10.1002\/14651858.CD006945.pub4-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.3324\/haematol.13290","article-title":"Consensus conference on the management of tumor lysis syndrome","volume":"93","author":"Tosi","year":"2008","journal-title":"Haematologica"},{"issue":"11","key":"10.1002\/14651858.CD006945.pub4-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/sj.bmt.1705379","article-title":"Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia","volume":"37","author":"Trifilio","year":"2006","journal-title":"Bone Marrow Transplantation"},{"issue":"1-2","key":"10.1002\/14651858.CD006945.pub4-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000089463","article-title":"Recombinant urate oxidase (rasburicase) for the prevention and treatment of tumor lysis syndrome in patients with hematologic malignancies","volume":"115","author":"Wang","year":"2006","journal-title":"Acta Haematologica"},{"issue":"7-8","key":"10.1002\/14651858.CD006945.pub4-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1345\/aph.1C336","article-title":"Rasburicase for the treatment and prevention of hyperuricemia","volume":"37","author":"Yim","year":"2003","journal-title":"The Annals of Pharmacotherapy"},{"issue":"1","key":"10.1002\/14651858.CD006945.pub4-BIB0050|cit50","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006945","article-title":"Urate oxidase for prevention and treatment of tumor lysis syndrome in children with cancer (Protocol)","author":"Cheuk","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD006945.pub4-BIB0051|cit51","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006945.pub2","article-title":"Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer","author":"Cheuk","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD006945.pub4-BIB0052|cit52","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006945.pub3","article-title":"Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer","author":"Cheuk","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD006945.pub4\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,25]],"date-time":"2022-12-25T06:34:12Z","timestamp":1671950052000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD006945.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Childhood Cancer Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,3,8]]},"references-count":52,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,3]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006945.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,8]]}}}